Targeted therapy for epithelial ovarian cancer

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 501-513

  Sharma, Sameer ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenesis; Cytokine; Epidermal growth factor receptor (EGFR); Immunotherapy; Ovarian cancer; p53 tumour suppressor gene; Suicide gene therapy; Targeted therapy; Vaccine

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; GAMMA INTERFERON; GANCICLOVIR; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MARIMASTAT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMFG1; ONYX 015; OREGOVOMAB; PACLITAXEL; PHENOXODIOL; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; TANOMASTAT; THYMIDINE KINASE; TIPIFARNIB; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VATALANIB; VIRUS ENZYME;

APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG RESPONSE; DRUG TARGETING; FATIGUE; FEMALE; FLU LIKE SYNDROME; GYNECOLOGIC CANCER; HUMAN; LETHARGY; METASTASIS; MINIMAL RESIDUAL DISEASE; MYALGIA; NAUSEA; OVARY CANCER; PERITONEAL CAVITY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; GENE THERAPY; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SUBSTRATE SPECIFICITY;

EID: 21244460426     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.501     Document Type: Review

References (131)

1. GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statistics, 2001. CA Cancer J. Clin. (2001) 51(1):15-36.
2. JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics, 2002. CA Cancer J. Clin. (2002) 52(1):23-47.
3. OZOLS RF: Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma: Cancer. In: Principles and Practices of Oncology, 6th Edition. Lippincott, Williams & Wilkins, Philadelphia (2001).
4. MCGUIRE WP, HOSKINS WJ, BRADY MF et al.: Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a Phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. (1996) 23(5 Suppl. 12):40-47.
5. STEWART LA, GUTHRIE D, PARMAR MK, WILLIAMS CJ: Chemotherapy in advanced ovarian cancer. Br. Med. J. (1992) 304(6819):119.
6. KUNG AL, ZETTERBERG A, SHERWOOD SW, SCHIMKE RT: Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation. Cancer Res. (1990) 50(22):7307-7317.
7. O'MALLEY DM, RUTHERFORD T, BROWN D, AL E: Phenoxodiol restores chemosensitivity in ovarian cancer. Proceedings of the American Society of Clinical Oncology, Chicago, USA (2003). Abstract 1844.
8. KAMSTEEG M, RUTHERFORD T, SAPI E et al.: Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 22(17):2611-2620.
9. LISTON P, FONG WG, KELLY NL et al.: Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat. Cell Biol. (2001) 3(2):128-133.
10. VERHAGEN AM, EKERT PG, PAKUSCH M et al.: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 102(1):43-53.
11. YANG QH, CHURCH-HAJDUK R, REN J, NEWTON ML, DU C: Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. (2003) 17(12):1487-1496.
12. LI J, FENG Q, KIM JM et al.: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology (2001) 142(1):370-380.
13. SASAKI H, SHENG Y, KOTSUJI F, TSANG BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoprosis in chemoresistant human ovarian cancer cells. Cancer Res. (2000) 60(20):5659-5666.
14. ASHKENAZI A, DIXIT VM: Death receptors: signaling and modulation. Science (1998) 281(5381):1305-1308.
15. USLU R, JEWETT A, BONAVIDA B: Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Gynecol. Oncol. (1996) 62(2):282-291.
16. SCHNEIDERMAN D, KIM JM, SENTERMAN M, TSANG BK: Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells. Apoptosis (1999) 4(4):271-281.
17. CHENG JQ, JIANG X, FRASER M et al.: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. (2002) 5(3-4):131-146.
18. CHENG JQ, RUGGERI B, KLEIN WM et al.: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA (1996) 93(8):3636-3641.
19. SHAYESTEH L, LU Y, KUO WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. (1999) 21(4):99-102.
20. BELLACOSA A, DE FEO D, GODWIN AK et al.: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer (1995) 64(4):280-285.
21. RUGGERI BA, HUANG L, WOOD M, CHENG JQ, TESTA JR: Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. (1998) 21(2):81-86.
22. PHILP AJ, CAMPBELL IG, LEET C et al.: The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in humangovarian and colon tumors. Cancer Res. (2001) 61(20):7426-7429.
23. JIMENEZ C, JONES DR, RODRIGUEZ-VICIANA P et al.: Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. (1998) 17(3):743-753.
24. ALI IU, SCHRIML LM, DEAN M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. (1999) 91(22):1922-1932.
25. KASTAN MB, CANMAN CE, LEONARD CJ: P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. (1995) 14(1):3-15.
26. MORGAN SE, KASTAN MB: p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res. (1997) 71:1-25.
27. ZEIMET AG, MARTH C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. (2003) 4(7):415-422.
28. BULLER RE, RUNNEBAUM IB, KARLAN BY et al.: A Phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. (2002) 9(7):553-566.
29. KOHLER MF, MARKS JR, WISEMAN RW et al.: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst. (1993) 85(18):1513-1519.
30. BIBLE KC, BOERNER SA, KIRKLAND K et al.: Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin. Cancer Res. (2000) 6(2):661-670.
31. MUJOO K, MANEVAL DC, ANDERSON SC, GUTTERMAN JU: Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene (1996) 12(8):1617-1623.
32. KIGAWA J, SATO S, SHIMADA M et al.: p53 gene status and chemosensitivity in ovarian cancer. Hum. Cell (2001) 14(3):165-171.
33. BULLER RE, SHAHIN MS, HOROWITZ JA et al.: Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene. Ther. (2002) 9(7):567-572.
34. VASEY PA, SHULMAN LN, CAMPOS S et al.: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. (2002) 20(6):1562-1569.
35. BEREK JS, SCHULTES BC, NICODEMUS CF: Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol. (2003) 21(10 Suppl.):168-174.
36. MAKHIJA S, SABBATINI P, AGHAJANIAN C, VENKATRAMAN E, SPRIGGS DR, BARAKAT R: Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Gynecol. Oncol. (2000) 79(1):28-32.
37. ALBERTS DS, LIU PY, HANNIGAN EV et al.: Intraperitoneal cisptatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. (1996) 335(26):1950-1955.
38. MARKMAN M, BUNDY BN, ALBERTS DS et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. (2001) 19(4):1001-1007.
39. ROSENFELD ME, FENG M, MICHAEL SI, SIEGAL GP, ALVAREZ RD, CURIEL DT: Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res. (1995) 1(12):1571-1580.
40. HASENBURG A, TONG XW, FISCHER DC et al.: Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol. (2001) 83(3):549-554.
41. ALVAREZ RD, GOMEZ-NAVARRO J, WANG M et al.: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther. (2000) 2(5):524-530.
42. BERCHUCK A, RODRIGUEZ GC, KAMEL A et al.: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Gynecol. Obstet. (1991) 164(2):669-674.
43. AUERSPERG N, WONG AS, CHOI KC, KANG SK, LEUNG PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. (2001) 22(2):255-288.
44. FISCHER-COLBRIE J, WITT A, HEINZL H et al.: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anti-Cancer Res. (1997) 17(1B):613-619.
45. BARTLETT JM, LANGDON SP, SIMPSON BJ et al.: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer (1996) 73(3):301-306.
46. PARK SJ, ARMSTRONG S, KIM CH et al.: Lack of EGF receptor contributes to drug sensitivity of human germline cells. Br. J. Cancer (2005) 92(2):334-341.
47. SCHILDER RJ, KOHN E, SILL ME: Phase II of gefnib in patients with recurrent ovarian or primary peritoneal cancer GOG 170c. Proceedings of the American Society of Clinical Oncology, Chicago, USA (2003). Abstract 1814.
48. MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21(14):2787-2799.
49. FINKLER N, GORDON A, CROZIER M et al.: Phase II Evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proceedings of the American Society of Clinical Oncology, San Francisco, USA (2001). Abstract 831.
50. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
51. BOOKMAN MA, DARCY KM, CLARKE-PEARSON D, BOOTHBY RA, HOROWITZ IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecology and Oncology Group. J. Clin. Oncol. (2003) 21(2):283-290.
52. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
53. SEE HT, KAVANAGH JJ, HU W, BAST RC: Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int. J. Gynecol. Cancer (2003) 13(6):701-734.
54. XU L, YONEDA J, HERRERA C, WOOD J, KILLION JJ, FIDLER IJ: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. (2000) 16(3):445-454.
55. ADJEI AA, CROGHAN GA, ERLICHMAN C et al.: A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. (2003) 9(7):2520-2526.
56. PALEY PJ: Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. Curr. Oncol. Rep. (2002) 4(2):165-174.
57. SIECZKIEWICZ GJ, HUSSAIN M, KOHN EC: Angiogenesis and metastasis. Cancer Treat. Res. (2002) 107:353-381.
58. FERRARA N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. (2002) 29(Suppl. 16):10-14.
59. HURWITZ H, FEHRENBACHER T, CARTWRIGHT J, AL E: Bevacizumab prolongs survival in first time colorectal cancer. Results of a Phase III trial. Proceedings of the American Society of Clinical Oncology, Chicago, USA (2003) Abstract 3646.
60. ZHONG X, LI X, WANG G et al.: Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int. J. Oncol. (2004) 25(2):445-451.
61. HERBST RS, ONN A, MENDELSOHN J: The role of growth factor signaling in malignancy. Cancer Treat. Res. (2003) 115:19-72.
62. BRITTEN CD, ROSEN LS, KABBINAVAR F et al. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proceedings of the American Society of Clinical Oncology, Orlando, USA (2002). Abstract 1922.
63. MURAKAMI H, YAMAMOTA T, SHIMOYAMA T, UEDA Y, YAMADA Y, TAMURA T: Phase I, pharmacokinetic, and biological studies of TSU-68, the oral vascular entothelial growth factor receptor tyrosine kinase inhibitor, administered after meals in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology, Chicago, USA (2003). Abstract 870.
64. HUSSAIN H, KOTZ H, MINASIAN L et al.: Occurance of ascites secondary to STI571 in ovarian cancer. Proceedings of the American Society of Clinical Oncology, Chicago, USA (2003). Abstract 880.
65. HEATH EI, O'REILLY S, HUMPHREY R et al.: Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (2001) 48(4):269-274.
66. RASMUSSEN HS, MCCANN PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. (1997) 75(1):69-75.
67. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric aniti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16(8):2825-2833.
68. DAVIS TA, MALONEY DG, GRILLO-LOPEZ AJ et al.: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin. Cancer Res. (2000) 6(7):2644-2652.
69. COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 97(1):101-106.
70. OSTERBORG A, DYER MJ, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously created chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. (1997) 15(4):1567-1574.
71. EHLEN T, GORDON A, FINGERT H et al.: Adjuvant treatment with monoclonal antibody, OvaRex MAb-B43.13 targeting CA125. Proceedings of the American Society of Clinical Oncology, Orlando, USA (2002). Abstract 31.
72. BOOKMAN M, RETTENMAIER M, GORDON A, AL E: Monoclonal antibody (Dresovomab) targeting of CA125 in patients with advanced epithelial ovarian cancer & elevated CA125 after response to initial therapy. Clin. Cancer Res. 7:3756s.
73. METHOD MW, GORDON A, FINKLER N, FINGERT H, NICODEMUS C, WHITESIDE T: Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex MAb-B43.13 in patients with epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology, Orlando, USA (2002). Abstract 80.
74. BEREK J, TAYLOR P, GORDON A et al.: Randomized prospective study of OvaRex MAb for consollidation of clinic remission in patients with ovarian cancer. Proceeding of the Society of Gynecologic Oncologists, San Diego, USA (2004).
75. EHLEN T, WHITESIDE T, SCHULTES B, AL E.: Induction of tumor protective immunity utilizing OvaRex in a cohort of patients with advanced recurrent ovarian cancer. Proceedings of the Society of Gynecologic Oncologists, Nashville, USA (2001).
76. GORDON A, WHITESIDE T, NICODEMUS C, SCHULTES B, NOUJAIM AA An interim assessment of OvaRex in the management of recurrent ovarian cancer. Proceedings of the American Society of Clinical Oncology, San Francisco, USA (2001). Abstract 2499.
77. BOLLE M, NIESEN A, KORZ W et al. Possible role of anti-CA125 monoclonal antibody B43.13 administration in long-term survival of relapsed ovarian cancer patients. Proceedings of the American Society of Clinical Oncology, New Orleans, USA (2000). Abstract 1867.
78. DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
79. TAYLOR-PAPADIMITRIOU J, PETERSON JA, ARKLIE J, BURCHELL J, CERIANI RL, BODMER WF: Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int. J. Cancer (1981) 28(1):17-21.
80. HIRD V, MARAVEYAS A, SNOOK D et al.: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer. (1993) 68(2):403-406.
81. NICHOLSON S, GOODEN CS, HIRD V et al.: Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol. Rep. (1998) 5(1):223-226.
82. SEIDEN M, BENIGNO BB, THE SMART STUDY INVESTIGATOR GROUP: A pivotal Phase II trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). Proceedings of the American Society of Clinical Oncology, New Orleans, USA (2004). Abstract 5008.
83. CAREY TE, TAKAHASHI T, RESNICK LA, OETTGEN HF, OLD LJ: Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA (1976) 73(9):3278-3282.
84. KNUTH A, DANOWSKI B, OETTGEN HF, OLD LJ: T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl. Acad. Sci. USA (1984) 81(11):3511-3515.
85. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647.
86. SAHIN U, TURECI O, SCHMITT H et al.: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA (1995) 92(25):11810-11813.
87. BOON T, VAN DER BRUGGEN P: Human tumor antigens recognized by T lymphocytes. J. Exp. Med. (1996) 183(3):725-729.
88. CHEN YT, GURE AO, TSANG S et al.: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. USA (1998) 95(12):6919-6923.
89. BRINKMANN U, VASMATZIS G, LEE B, PASTAN I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. (1999) 59(7):1445-1448.
90. VAN DEN EYNDE B, PEETERS O, DE BACKER O, GAUGLER B, LUCAS S, BOON T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. (1995) 182(3):689-698.
91. CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94(5):1914-1918.
92. LETHE B, LUCAS S, MICHAUX L et al.: LAGE-1, a new gene with tumor specificity. Int. J. Cancer. (1998) 76(6):903-908.
93. TURECI O, SAHIN U, SCHOBERT I et al.: The SSX-2 gene, which is involved in the r(X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. (1996) 56(20):4766-4772.
94. GURE AO, TURECI O, SAHIN U et al.: SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer (1997) 72(6):965-971.
95. GURE AO, WEI IJ, OLD LJ, CHEN YT: The SSX gene family: characterization of 9 complete genes. Int. J. Cancer (2002) 101(5):448-453.
96. ZENDMAN AJ, CORNELISSEN IM, WEIDLE UH, RUITER DJ, VAN MUIJEN GN: CTp11, a novel member of the family of human cancer/testis antigens. Cancer Res. (1999) 59(24):6223-6229.
97. ZENDMAN AJ, RUITER DJ, VAN MUIJEN GN: Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell Physiol. (2003) 194(3):272-288.
98. FELLER AJ, DUAN Z, PENSON R, TOH HC, SEIDEN MV: TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma. Anti-Cancer Res. (2000) 20(6B):4147-4151.
99. BOEL P, WILDMANN C, SENST ML et al.: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 2(2):167-175.
100. TURECI O, SAHIN U, ZWICK C, KOSLOWSKI M, SEITZ G, PFREUNDSCHUH M: Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA (1998) 95(9):5211-5216.
101. ONO T, KURASHIGE T, HARADA N et al.: Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc. Natl. Acad. Sci. USA (2001) 98(6):3282-3287.
102. SCANLAN MJ, GORDON CM, WILLIAMSON B et al.: Identification of cancer/testis genes by database mining and mRNA expression analysis. Int. J. Cancer (2002) 98(4):485-492.
103. JAGER D, UNKELBACH M, FREI C et al.: Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immun. (2002) 2:5.
104. ODUNSI K, JUNGBLUTH AA, STOCKERT E et al.: NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy in Epithelial Ovarian Cancer. Cancer Res. (2003) 63(18):6076-6083.
105. JAGER E, NAGATA Y, GNJATIC S et al.: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA (2000) 97(9):4760-4765.
106. STOCKERT E, JAGER E, CHEN YT et al.: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. (1998) 187(8):1349-1354.
107. FOON KA, BHATTACHARYA-CHATTERJEE M: Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res. (2001) 7:1154-1162.
108. FOON KA, BHATTACHARYA-CHATTERJEE M: Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res. (2001) 7(5):1112-1115.
109. LINDENMANN J: Speculations on idiotypes and homobodies. Ann. Immunol. (Paris). (1973) 124(2):171-184.
110. JERNE NK: Towards a network theory of the immune system. Ann. Immunol. (Paris). (1974) 125C(1-2):373-389.
111. HERLYN D, HARRIS D, ZALOUDIK J et al.: Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J. Immunother. Emphasis Tumor Immunol. (1994) 15(4):303-311.
112. BIREBENT B, SOMASUNDARAM R, PUREV E et al.: Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. Crit. Rev. Oncol. Hematol. (2001) 39(1-2):107-113.
113. WAGNER U, KOHLER S, REINARTZ S et al.: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res. (2001) 7(5):1112-1115.
114. WAGNER U, KOHLER S, REINARTZ S et al.: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res. (2001) 7(5):1154-1162.
115. ALLAVENA P, PECCATORI F, MAGGIONI D et al.: Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. (1990) 50(22):7318-7323.
116. NEHME A, JULIA AM, JOZAN S, CHEVREAU C, BUGAT R, CANAL P: Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur. J. Cancer (1994) 30A(4):520-525.
117. SAITO T, BERENS ME, WELANDER CE: Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res. (1986) 46(3):1142-1147.
118. BEREK JS, HACKER NF, LICHTENSTEIN A et al.: Intraperitoneal recombinant alpha-interferon for 'salvage' immunotherapy in stage III epithelial ovarian cancer: a Gynecology and Oncology Group Study. Cancer Res. (1985) 45(9):4447-4453.
119. BEREK JS: Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Eur. J. Cancer (1992) 28A(4-5):719-721.
120. BEREK JS, WELANDER C, SCHINK JC, GROSSBERG H, MONTZ FJ, ZIGELBOIM J: A Phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol. Oncol. (1991) 40(3):237-243.
121. BEREK JS, MARKMAN M, STONEBRAKER B et al.: Intraperitoneal interferon-alpha in residual ovarian carcinoma: a Phase II gynecologic oncology group study. Gynecol. Oncol. (1999) 75(1):10-14.
122. NARDI M, COGNETTI F, POLLERA CF et al.: Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a Phase II study. J. Clin. Oncol. (1990) 8(6):1036-1041.
123. WINDBICHLER GH, HAUSMANINGER H, STUMMVOLL W et al.: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized Phase III trial. Br. J. Cancer (2000) 82(6):1138-1144.
124. HALL GD, BROWN JM, COLEMAN RE et al.: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised Phase III study. Br. J. Cancer (2004) 91(4):621-626.
125. MARTH C, ZEIMET AG, HEROLD M et al.: Different effects of interferons, interleukin-1 beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int. J. Cancer (1996) 67(6):826-830.
126. MARTH C, WIDSCHWENDTER M, KAERN J et al.: Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Br. J. Cancer (1997) 76(10):1328-1332.
127. MARTH C, MULLER-HOLZNER E, GREITER E et al.: Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res. (1990) 50(21):7037-7041.
128. ENDO TA, MASUHARA M, YOKOUCHI M et al.: A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 387(6636):921-924.
129. NAKA T, NARAZAKI M, HIRATA M et al.: Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 387(6636):924-929.
130. STARR R, WILLSON TA, VINEY EM et al.: A family of cytokine-inducible inhibitors of signalling. Nature (1997) 387(6636):917-921.
131. ENGEL J, ECKEL R, SCHUBERT-FRITSCHLE G et al.: Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur. J. Cancer (2002) 38(18):2435-2445.